Interpace Diag Grp (NASDAQ:IDXG) shares traded -3.87% down during most recent session to reach at the closing price of $0.91. The stock exchanged hands 1.27 Million shares versus average trading capacity of 1.72 Million shares, yielding a market cap of $17.79 Million. Wall Street analysts covering the stock are projecting that the stock will reach $3 within the next 52-weeks. The mean target projections are based on 1 opinions.
Taking a broader look brokerage firms’ analysts on the street with an expectant view have Interpace Diag Grp (NASDAQ:IDXG) high price target of $3 and with a conservative view have low price target of $3.
On the other hand the company has Relative Strength Index (RSI 14) of 37.6 along with Average True Range (ATR 14) of 0.07, Consequently Interpace Diag Grp (NASDAQ:IDXG)’s weekly and monthly volatility is 9.09%, 6.42% respectively. The company’s beta value is at 1.87.
In terms of Buy, Sell or Hold recommendations, Interpace Diag Grp (NASDAQ:IDXG) has analysts’ mean recommendation of 2. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.
Currently Interpace Diag Grp (NASDAQ:IDXG)’s shares owned by insiders are 1.1%, whereas shares owned by institutional owners are 8.9%. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded 124.39%.
Interpace Diag Grp (NASDAQ:IDXG) 52-week high price stands at $19.80 and low price stands at $0.70, its price distance from 52-week high is -95.41% while its distance from 52-week low price is 29.77%. The stock hit its 52-week high on 12/09/16, and 52-week low on 11/22/16.
Interpace Diag Grp (NASDAQ:IDXG)’s trailing twelve month revenues are $13.5 Million, whereas its price to sales ratio for the same period is 1.32. Its book value per share for the most recent quarter is $5.72 while its price to book ratio for the same period is 0.16, as for as the company’s cash per share for the most recent quarter is $0, however its price to cash per share ratio for the same period is 0. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.